Delivery Order SPE2DB20D2104-SPE2DB22FR08D
- Not listed
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,402.82 firm-fixed-price delivery order is for the supply of 4,562,493,984 units of Sevelamer HCL 800 mg tablets. The award has an ultimate completion date of October 17, 2023. There is no set-aside designation for this contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,438.91, is for the delivery of sevelamer carbonate 800 mg tablets. It is a firm fixed-price delivery order with a completion date of January 3, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is also registered as a for-profit organization in the System for Award Management...
- This federal contract award, valued at $2,105.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of sevelamer carbonate 800 mg tablets, which are used to treat certain medical conditions. The contract is a Firm Fixed Price Delivery Order with a completion date of September 23, 2024. No set-aside designation was used for this award. Amerisourcebergen Drug Corp holds a significant Indefinite...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the provision of Sevelamer Carbonate 800 mg tablets. The contract has a ceiling value of $1,766.92 and was awarded as a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $7,550.32 firm fixed-price delivery order is for the supply of sevelamer hydrochloride 800 mg tablets, a medication used to treat certain kidney conditions. The contract has an ultimate completion date of March 10, 2022 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent...
- This contract award to AmerisourceBergen Drug Corp's Corporate Office Division provides for the delivery of sevelamer carbonate 800 mg tablets to the Department of Defense's Medical Supply Chain (DLA Troop Support Medical). The $2,192.13 firm-fixed-price delivery order is part of a larger Indefinite Delivery Contract valued at up to $999,999,999 through December 2025 for pharmaceutical and medical supplies. This contract does not have a set-aside designation. AmerisourceBergen, one of the...
- This federal contract award is for the delivery of Sevelamer HCL 800 mg tablets to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award has a ceiling value of $2,650.06 and an ultimate completion date of September 19, 2023. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which...
- This federal contract award, with ID SPE2DB22D3501|SPE2DB24FVQ36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $1,440.95, is for the delivery of sevelamer 2.4 GM powder packets. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Sevelamer HCL 800 mg tablets (180-count) with a contract ceiling value of $6,710.88. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by September 9, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The contract, valued at $1,890.00, is for the supply of 4,567,005,600 packets of 0.8 gram sevelamer powder. The award has no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR08DDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of 4,555,506,699 tablets of sevelamer carbonate 800 mg. The contract, valued at $7,752.91, was awarded by the Defense Logistics Agency (DLA) on November 23, 2021, with a completion date of November 24, 2021. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2025. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 11/23/21 |